Davidson Investment Advisors lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 326,333 shares of the biopharmaceutical company’s stock after buying an additional 72,016 shares during the period. Gilead Sciences comprises about 2.9% of Davidson Investment Advisors’ investment portfolio, making the stock its 6th biggest position. Davidson Investment Advisors’ holdings in Gilead Sciences were worth $26,439,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Arvest Bank Trust Division grew its position in Gilead Sciences by 1.1% in the second quarter. Arvest Bank Trust Division now owns 238,542 shares of the biopharmaceutical company’s stock worth $16,884,000 after acquiring an additional 2,665 shares in the last quarter. Union Bankshares Corp grew its position in Gilead Sciences by 4.4% in the second quarter. Union Bankshares Corp now owns 6,234 shares of the biopharmaceutical company’s stock worth $441,000 after acquiring an additional 260 shares in the last quarter. Kempner Capital Management Inc. grew its position in Gilead Sciences by 3.8% in the second quarter. Kempner Capital Management Inc. now owns 66,890 shares of the biopharmaceutical company’s stock worth $4,734,000 after acquiring an additional 2,428 shares in the last quarter. Swedbank grew its position in Gilead Sciences by 0.4% in the second quarter. Swedbank now owns 2,214,959 shares of the biopharmaceutical company’s stock worth $156,775,000 after acquiring an additional 9,857 shares in the last quarter. Finally, NEXT Financial Group Inc grew its position in Gilead Sciences by 74.2% in the second quarter. NEXT Financial Group Inc now owns 16,600 shares of the biopharmaceutical company’s stock worth $1,175,000 after acquiring an additional 7,072 shares in the last quarter. 76.06% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider John F. Milligan sold 220,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 591,666 shares of company stock valued at $44,466,567. 1.30% of the stock is currently owned by company insiders.

Several brokerages recently issued reports on GILD. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a research report on Wednesday, January 17th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $79.02 to $96.00 in a research report on Tuesday, January 16th. Finally, Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have issued a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $85.53.

Shares of Gilead Sciences, Inc. (GILD) opened at $81.41 on Tuesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market cap of $106,320.00, a PE ratio of 9.26, a PEG ratio of -1.76 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 earnings per share. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.55%. Gilead Sciences’s dividend payout ratio is currently 23.66%.

TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) is Davidson Investment Advisors’ 6th Largest Position” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/23/gilead-sciences-inc-gild-is-davidson-investment-advisors-6th-largest-position.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.